Leukapheresis Market

Leukapheresis Market

Leukapheresis Market to Reach USD 136 Million by 2032, driven by the growth in investment in healthcare infrastructure across the globe: Global Insight Services

New York, April 2023: According to a new research study by Global Insight Services (GIS), the global leukapheresis market is expected to grow rapidly over the next 10 years to reach a value of more than USD 136 million by 2032.

The method of leukapheresis is used to remove white blood cells from a blood sample. It is done to lower the number of elevated white blood cells, to gain cells for different types of research, and to collect autologous blood cells for transplanting back into the patient. Leukapheresis is a form of apheresis that removes a component of blood and then reincorporates the remaining blood into circulation. White blood cells are isolated during chemotherapy in order to protect them from potential harm from the high dosage of chemotherapy medications. They are then returned to the patient’s body.

Request Sample Pages of this Research Report:


Leukapheresis Market: Key Trends and Drivers

Leukemia incidence has drastically increased across the globe. The American Cancer Society predicts that there will be 61,090 new cases of leukemia in the US in 2021. In addition, it is predicted that leukemia would be responsible for 23,660 fatalities in the US in 2021. Between 2008 and 2020, the incidence rate of leukemia in children increased by 1% year. It is logical to assume that the increased prevalence of hyper leukocytic leukemia will increase the need for therapeutic leukapheresis operations in the next years and support the expansion of the leukapheresis market.

Despite its therapeutic benefits, leukapheresis is still not widely used as a treatment, especially for hyper leukocytic leukemia. But industry participants are starting to pay more attention to how therapeutic leukapheresis is used to treat pediatric patients. The risks and side effects of conventional treatments, such as chemotherapy for children, can be primarily blamed for this. Children’s stem cells can be obtained through leukapheresis and utilized to treat or remove extra WBCs in patients with juvenile lymphoma or other cancers. Given that so few hospitals now offer leukapheresis treatment for children in both established and emerging economies, leukapheresis is an area of focus in this market due to the potential and benefits it offers in this application.

Leukapheresis Market: Restraints and Challenges

Apheresis equipment typically costs between 20,000 and 150,000 dollars. Smaller hospitals and blood banks therefore avoid using this method of blood collection. Furthermore, for efficient therapy and the collection/removal of WBCs via apheresis, trained and skilled physicians, personnel, and nurses are also needed. Leukapheresis is an expensive technology for short-term use due to all of these issues. Similar to this, leukapheresis at hospitals and cancer treatment facilities has a very high cost because it requires extra disposables, which can cost between USD 1,500 and 3,000 for each patient. As a result, relatively few small blood banks, research institutions, and hospitals have adopted leukapheresis and leukoplakia, which will limit the growth of the leukapheresis market throughout the course of the projected period.

Leukapheresis Market Report Findings


The leukapheresis device segment is anticipated to dominate the market during the forecast period

Based on the type, it is segmented into leukapheresis devices, apheresis devices, leukoreduction filters, leukapheresis columns & cell separators. The leukapheresis device segment is anticipated to dominate the market during the forecast period. White blood cells (leukocytes) are separated from whole blood using leukapheresis equipment. Leukoreduced blood cell products, such as leukoreduced plasma and leukoreduced RBCs, are also created using these instruments. The rise in therapeutic leukapheresis procedures used to treat inflammatory bowel illnesses, immune-mediated inflammatory diseases, and leukemia is mostly responsible for the market expansion for leukapheresis equipment. Another important element driving market expansion is the blood collection facilities’ growing adoption of leukapheresis equipment.

The research application segment is anticipated to dominate the market during the forecast period

Based on the application, it is segmented into research applications and therapeutic applications. The research application segment is anticipated to dominate the market during the forecast period. The significant market share of this sector is related to the growing use of leukapheresis products in the research and development of cell-based immunotherapies, as well as to the growing number of clinical studies using leukomas as a primary raw material.

The blood component providers & blood centers segment is anticipated to dominate the market during the forecast period

Based on the end users, it is segmented into blood component providers & blood centers, academic & research institutes, pharmaceutical & biotechnology companies, hospitals & transfusion centers. The blood component providers & blood centers segment is anticipated to dominate the market during the forecast period. The rising amount of blood donations, the rising need for leukomas for the creation of CAR T-cell treatments, and the rising need for blood components in medical illnesses like cancer are all responsible for the large share of this market.

The Asia Pacific region is anticipated to dominate the market during the forecast period

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. The Asia Pacific region is anticipated to dominate the market during the forecast period. Due to factors including an aging population, a rise in leukemia prevalence, improved healthcare infrastructure, an increase in clinical trials in China, and rising public and private investments for the development of CAR-T therapy, emerging markets in the Asia Pacific region have become significant growth hotspots in the market.

Have a question for our analyst:


Competitive Landscape

The key players studied in the report are Fresenius, Asahi Kasei Medical, Haemonetics, STEMCELL Technologies, Terumo BCT, Macopharma, HemaCare, Caltag Medsystem, StemExpress, Key Biologics LLC, ZenBio Inc, Digital Pharmacist Inc, BioIVT, Precision for Medicine Inc, and Lmb Technologie GmbH among others.

Recent Development

  • September 2020, All Cells, LLC added cryopreserved leukoplakia to its product portfolio to ensure access to high-quality primary cells without potential delivery delays.
  • June 2020, Haemonetics Corporation announced an agreement to sell its Fajardo, Puerto Rico manufacturing operations of blood filters to GVS S.p.A.
  • June 2020, Stem Express, LLC. Added frozen leukopaks, LE00 (2.5C, 5C, 10C), which are frozen after fresh blood collection and provide an enriched source of peripheral blood mononuclear cells for medical research.
  • January 2020, Fresenius Kabi inaugurated the expansion of its transfusion and apheresis disposables plant in the Dominican Republic in Santa Domingo.
  • February 2019, Terumo BCT, Inc. expanded its global footprint by opening its first regional office in sub-Saharan Africa, in Nairobi, Kenya.

Leukapheresis Market Report Coverage

  • The report offers a comprehensive quantitative as well as qualitative analysis of the current global Leukapheresis market outlook and estimations from 2022 to 2032, which helps to recognize the prevalent opportunities.
  • A thorough analysis of market trends and restraints is provided.
  • Region-wise, as well as country-wise conditions, are broadly evaluated in this report.
  • The forecasts in this report are made by examining the recent trends along with future Leukapheresis market potential from 2022 to 2032 in terms of revenue.
  • Porter’s five forces analysis, SWOT analysis, COVID-19 impact analysis, Russia-Ukraine war impact, and PESTLE analysis of the Leukapheresis market are also analyzed.
  • Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the global Leukapheresis industry.

Global Leukapheresis Market Segmentation

By Type

  • Leukapheresis Devices
  • Apheresis Devices
  • Leukoreduction Filters
  • Leukapheresis Columns & Cell Separators

By Application

  • Research Applications
  • Therapeutic Applications

By End Users

  • Blood Component Providers & Blood Centers
  • Academic & Research Institutes
  • Pharmaceutical & Biotechnology Companies
  • Hospitals & Transfusion Centers

By Region

  • North America
    • The U.S.
    • Canada
    • Mexico
  • Europe
    • The UK
    • Germany
    • France
    • Spain
    • Rest of Europe
  • The Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Rest of the World
    • Latin America
    • The Middle East
    • Africa

Key Players